{"id":9728,"date":"2026-10-07T10:46:57","date_gmt":"2026-10-07T14:46:57","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/?p=9728"},"modified":"2026-10-29T17:43:55","modified_gmt":"2026-10-29T16:43:55","slug":"gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/","title":{"rendered":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>8,2 millions d\u2019euros d\u2019encaissements bruts au titre des programmes d\u2019acc\u00e8s d\u00e9rogatoires payants depuis le d\u00e9but des traitements en mars 2026, dont 1,7 million d\u2019euros au troisi\u00e8me trimestre.<\/li>\n\n\n\n<li>Les programmes d\u2019acc\u00e8s d\u00e9rogatoires payants continuent de contribuer \u00e0 la tr\u00e9sorerie et soutiennent les activit\u00e9s op\u00e9rationnelles de la Soci\u00e9t\u00e9.<\/li>\n\n\n\n<li>0,7 million d\u2019euros de tr\u00e9sorerie et d\u2019\u00e9quivalents de tr\u00e9sorerie au 30 septembre 2026.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le mercredi 7 octobre 2026, 23h55 CEST<\/strong> \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie au 30 septembre 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Situation de tr\u00e9sorerie et programmes d\u2019acc\u00e8s d\u00e9rogatoires au 30 septembre 2026<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La tr\u00e9sorerie et les \u00e9quivalents de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9levaient \u00e0 0,7 million d\u2019euros au 30 septembre 2026, contre 1,7 million d\u2019euros au 30 juin 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au cours du troisi\u00e8me trimestre 2026, la Soci\u00e9t\u00e9 a encaiss\u00e9 1,7 million d\u2019euros au titre du programme d\u2019acc\u00e8s compassionnel (AAC) en France. Depuis le d\u00e9but des traitements en mars 2026, les encaissements bruts cumul\u00e9s au titre des programmes d\u2019acc\u00e8s d\u00e9rogatoires payants ont atteint 8,2 millions d\u2019euros.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le recul de la tr\u00e9sorerie et des \u00e9quivalents de tr\u00e9sorerie sur le trimestre refl\u00e8te principalement la pause estivale des traitements du programme d\u2019AAC en juillet et en ao\u00fbt, la poursuite du transfert de technologie de fabrication chez Catalent, achev\u00e9 avec succ\u00e8s fin septembre 2026, ainsi que la pr\u00e9paration en cours de l\u2019\u00e9tude de phase III RECOVER.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les programmes d\u2019acc\u00e8s d\u00e9rogatoires payants pour GS010\/LUMEVOQ<sup>\u00ae<\/sup><a href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/#_ftn1\">[1]<\/a> continuent de de contribuer \u00e0 la tr\u00e9sorerie, soutenant ainsi les activit\u00e9s op\u00e9rationnelles de la Soci\u00e9t\u00e9. Des traitements devraient avoir lieu dans de nouveaux pays au quatri\u00e8me trimestre 2026, au titre de programmes d\u2019acc\u00e8s d\u00e9rogatoires payants. Les encaissements sont pr\u00e9sent\u00e9s avant d\u00e9duction des remises.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Besoins de financement et horizon de tr\u00e9sorerie<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Comme annonc\u00e9 le 29 septembre 2026, sur la base de la position de tr\u00e9sorerie actuelle de la Soci\u00e9t\u00e9 et de ses flux de tr\u00e9sorerie pr\u00e9visionnels, ses ressources financi\u00e8res disponibles sont insuffisantes pour couvrir ses besoins op\u00e9rationnels au cours des douze prochains mois. Les encaissements issus des programmes d\u2019acc\u00e8s d\u00e9rogatoires et le Cr\u00e9dit d\u2019Imp\u00f4t Recherche (CIR) devraient plus que couvrir les d\u00e9penses op\u00e9rationnelles de la Soci\u00e9t\u00e9, et le besoin net de financement est estim\u00e9 \u00e0 environ 16 millions d\u2019euros, correspondant principalement aux co\u00fbts de pr\u00e9paration de l\u2019essai de phase III RECOVER et de la fabrication associ\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dans l\u2019hypoth\u00e8se o\u00f9 la Soci\u00e9t\u00e9 obtiendrait, d\u2019ici fin novembre 2026, soit un financement relais \u00e0 court terme d\u2019un montant maximal de 2 millions d\u2019euros, soit des encaissements issus, dans le cadre des programmes d\u2019acc\u00e8s d\u00e9rogatoires, de traitements suppl\u00e9mentaires par rapport \u00e0 ceux retenus dans ses projections, ses ressources de tr\u00e9sorerie seraient suffisantes jusqu\u2019\u00e0 fin mars 2027, date \u00e0 laquelle sont attendus les premiers paiements significatifs li\u00e9s \u00e0 la pr\u00e9paration de l\u2019essai RECOVER. Si le financement structurel n\u2019\u00e9tait pas obtenu d\u2019ici mars 2027, la Soci\u00e9t\u00e9 reporterait le d\u00e9marrage de l\u2019essai RECOVER&nbsp;; dans ce cas, les encaissements issus des programmes d\u2019acc\u00e8s d\u00e9rogatoires continueraient de couvrir les d\u00e9penses op\u00e9rationnelles de la Soci\u00e9t\u00e9, sous r\u00e9serve du timing des traitements et de la poursuite de ces programmes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Comme d\u00e9crit dans la note 3.4 des comptes consolid\u00e9s semestriels r\u00e9sum\u00e9s, les besoins de financement de la Soci\u00e9t\u00e9 indiquent l\u2019existence d\u2019une incertitude significative susceptible de jeter un doute important sur sa capacit\u00e9 \u00e0 poursuivre son exploitation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/#_ftnref1\">[1]<\/a> GS010\/LUMEVOQ<sup>\u00ae<\/sup> est une th\u00e9rapie g\u00e9nique exp\u00e9rimentale qui n\u2019a obtenu d\u2019autorisation de mise sur le march\u00e9 dans aucun pays.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le mercredi 7 octobre 2026, 23h55 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie au 30 septembre 2026. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[98],"class_list":["post-9728","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","post-year-98"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le mercredi 7 octobre 2026, 23h55 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie au 30 septembre 2026. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-07T14:46:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T16:43:55+00:00\" \/>\n<meta name=\"author\" content=\"competenow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"competenow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/\"},\"author\":{\"name\":\"competenow\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ee106250c85d191caf702f3988f78249\"},\"headline\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026\",\"datePublished\":\"2026-10-07T14:46:57+00:00\",\"dateModified\":\"2026-10-29T16:43:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/\"},\"wordCount\":687,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/\",\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-10-07T14:46:57+00:00\",\"dateModified\":\"2026-10-29T16:43:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ee106250c85d191caf702f3988f78249\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ee106250c85d191caf702f3988f78249\",\"name\":\"competenow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"caption\":\"competenow\"},\"sameAs\":[\"http:\\\/\\\/www.gensight-biologics.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics","og_description":"Paris, France, le mercredi 7 octobre 2026, 23h55 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie au 30 septembre 2026. [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/","og_site_name":"GenSight Biologics","article_published_time":"2026-10-07T14:46:57+00:00","article_modified_time":"2026-10-29T16:43:55+00:00","author":"competenow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"competenow","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/"},"author":{"name":"competenow","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ee106250c85d191caf702f3988f78249"},"headline":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026","datePublished":"2026-10-07T14:46:57+00:00","dateModified":"2026-10-29T16:43:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/"},"wordCount":687,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/","name":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-10-07T14:46:57+00:00","dateModified":"2026-10-29T16:43:55+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ee106250c85d191caf702f3988f78249"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ee106250c85d191caf702f3988f78249","name":"competenow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","caption":"competenow"},"sameAs":["http:\/\/www.gensight-biologics.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=9728"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9728\/revisions"}],"predecessor-version":[{"id":9945,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9728\/revisions\/9945"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=9728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=9728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=9728"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=9728"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=9728"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=9728"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=9728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}